APLS Overview
Upcoming Projects (APLS)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (APLS)
-
A Third Look: Discussing the recent label update for SYFOVRE (pegcetacoplan injection) addressing cases of eye inflammation and blockage in a retinal vein in patients who have received the drug.
Ticker: APLS
Executed On: Mar 14, 2024 at 03:00 PM EDT -
A Second Look: Discussing the recent label update for SYFOVRE (pegcetacoplan injection) addressing cases of eye inflammation and blockage in a retinal vein in patients who have received the drug.
Ticker: APLS
Executed On: Feb 27, 2024 at 10:00 AM EST -
Discussing the recent label update for SYFOVRE (pegcetacoplan injection) addressing cases of eye inflammation and blockage in a retinal vein in patients who have received the drug.
Ticker: APLS
Executed On: Feb 21, 2024 at 04:30 PM EST -
A third look at the standard of care and the 24 month topline result of Iveric Bio's FDA Approved IZERVAY (avacincaptad pegol intravitreal solution) to treat Geographic Atrophy
Tickers: ALPMY, APLS, ISEE
Executed On: Nov 08, 2023 at 04:00 PM EST -
A Second View: Checking in with a prescriber for APLS' Syfovre in Geographic Atrophy
Ticker: APLS
Executed On: Nov 02, 2023 at 02:00 PM EDT -
Checking in with a prescriber for APLS' Syfovre in Geographic Atrophy
Ticker: APLS
Executed On: Nov 02, 2023 at 01:15 PM EDT -
A second look at the standard of care and the 24 month topline result of Iveric Bio's FDA Approved IZERVAY (avacincaptad pegol intravitreal solution) to treat Geographic Atrophy
Tickers: ALPMY, ISEE, APLS
Executed On: Sep 28, 2023 at 02:30 PM EDT -
A look at the standard of care and the 24 month topline result of Iveric Bio's FDA Approved IZERVAY (avacincaptad pegol intravitreal solution) to treat Geographic Atrophy
Tickers: ALPMY, ISEE, APLS
Executed On: Sep 28, 2023 at 10:35 AM EDT -
A Third Look: Understanding if the use of Apellis' Syfovre will be impacted by the recent report of six cases of occlusive retinal vasculitis
Ticker: APLS
Executed On: Jul 20, 2023 at 02:00 PM EDT -
A Second Look: Understanding if the use of Apellis' Syfovre will be impacted by the recent report of six cases of occlusive retinal vasculitis
Ticker: APLS
Executed On: Jul 18, 2023 at 10:30 AM EDT -
Understanding if the use of Apellis' Syfovre will be impacted by the recent report of six cases of occlusive retinal vasculitis
Ticker: APLS
Executed On: Jul 18, 2023 at 08:00 AM EDT -
Discussing the potential of EMPAVELI and Zimura in GA with attention to the Phase 3 DERBY/OAKS studies of intravitreal pegcetacoplan and the GATHER2 Phase 3 study of avacincaptad pegol in GA.
Tickers: ISEE, APLS
Executed On: Oct 13, 2022 at 10:00 AM EDT -
A 2nd look at the recently announced 2-year results of pegcetacoplan(EMPAVELI) for patients with GA in the Phase 3 DERBY and OAKS Studies.
Ticker: APLS
Executed On: Sep 01, 2022 at 10:30 AM EDT -
A look at the recently announced 2-year results of pegcetacoplan(EMPAVELI) for patients with GA in the Phase 3 DERBY and OAKS Studies.
Ticker: APLS
Executed On: Aug 30, 2022 at 08:00 AM EDT -
A Fourth View: A look into the use of Empevali (pegcetacoplan) in treating patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).
Ticker: APLS
Executed On: May 26, 2022 at 10:00 AM EDT -
A Third View: A look into the use of Empevali (pegcetacoplan) in treating patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).
Ticker: APLS
Executed On: May 18, 2022 at 04:10 PM EDT -
A Second View: A look into the use of Empevali (pegcetacoplan) in treating patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).
Ticker: APLS
Executed On: May 17, 2022 at 01:15 PM EDT -
A third look into the potential use of intravitreal pegcetacoplan in patients with geographic atrophy after Apellis announces longer-term data from DERBY and OAKS studies.
Ticker: APLS
Executed On: May 13, 2022 at 08:45 AM EDT -
A look into the use of Empevali (pegcetacoplan) in treating patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).
Ticker: APLS
Executed On: May 11, 2022 at 05:00 PM EDT -
A second look into the potential use of intravitreal pegcetacoplan in patients with geographic atrophy after Apellis announces longer-term data from DERBY and OAKS studies.
Ticker: APLS
Executed On: May 06, 2022 at 04:00 PM EDT -
A look into the potential use of intravitreal pegcetacoplan in patients with geographic atrophy after Apellis announces longer-term data from DERBY and OAKS studies.
Ticker: APLS
Executed On: May 06, 2022 at 12:30 PM EDT
Upcoming & Overdue Catalysts (APLS)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (APLS)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
